索拉非尼对中晚期肝细胞癌患者的影响

摘要

目的：观察中晚期肝细胞癌患者索拉非尼治疗后药物相关性不良反应的发生率，并评价服药后6个月的疗效及对患者生活质量的影响。方法：对36例服用索拉非尼的肝细胞癌患者所发生的药物相关性不良反应进行分级、记录与统计分析。按照RECIST标准评价服药6个月后的疗效。EORTC QLQ-C30量表评估索拉非尼治疗前与治疗后6个月患者的生活质量。结果：患者服用索拉非尼后出现手足皮肤反应、腹泻、皮疹、高血压等不良反应。患者服药6个月后总反应率为75％。经索拉非尼治疗后患者在躯体、角色、认知、情绪及社会功能评分有所上升，有统计学差异（ P＜0.05）。除腹泻外其他症状评分均有下降，有统计学差异（ P%Objective:To observe the incidence of sorafenib-related adverse drug reactions of patients with termi-nal-stage hepatocellular carcinoma after the treatment,and evaluate the effect and the influence on quality of life of patients six months after sorafenib treatment. Methods:Sorafenib-related adverse drug reactions in 36 hepatocellular carcinoma cases after treatment were graded,recorded and statistically analyzed. The effect of sorafenib treatment was evaluated according to RECIST criteria six months later. The quality of life of the patients were compared before and six months after treatment using EORTC QLQ-C30. Results:The adverse drug reactions were hand-foot skin reac-tion,diarrhea,rashes,high blood pressure and so on after sorafenib treatment. The overall response rate was 75% six months after treatment. The scores of physical,role,cognitive,emotion and social functioning were increased and the scores of symptom scales were decreased except diarrhea in patients after sorafenib treatment ,which had statistical difference( P <0 . 0 5 ). The global quality of life were much significantly improved than before the treatment( P<0. 05). Conclusion:Sorafenib as a molecular targeted therapy drug,can prolong survival in patients with hepatocellu-lar carcinoma and the tolerability to adverse drug reactions are better,while the quality of life on patients can improve.